Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura

    loading  Checking for direct PDF access through Ovid


We report the case of an 84-year-old man with refractory immune thrombocytopenia purpura (ITP) who was treated with rituximab and subsequently developed severe interstitial lung disease. There has been increasing use of rituximab in the treatment of ITP with success rates of up to 62% in adult patients with recurrent ITP. Interstitial lung disease is a rare but recognised complication of rituximab but has been rarely reported in the setting of ITP.

Related Topics

    loading  Loading Related Articles